284 related articles for article (PubMed ID: 11280770)
1. Activation of beta-catenin during hepatocarcinogenesis in transgenic mouse models: relationship to phenotype and tumor grade.
Calvisi DF; Factor VM; Loi R; Thorgeirsson SS
Cancer Res; 2001 Mar; 61(5):2085-91. PubMed ID: 11280770
[TBL] [Abstract][Full Text] [Related]
2. Activation of beta-catenin provides proliferative and invasive advantages in c-myc/TGF-alpha hepatocarcinogenesis promoted by phenobarbital.
Calvisi DF; Ladu S; Factor VM; Thorgeirsson SS
Carcinogenesis; 2004 Jun; 25(6):901-8. PubMed ID: 14742323
[TBL] [Abstract][Full Text] [Related]
3. Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha.
Santoni-Rugiu E; Nagy P; Jensen MR; Factor VM; Thorgeirsson SS
Am J Pathol; 1996 Aug; 149(2):407-28. PubMed ID: 8701981
[TBL] [Abstract][Full Text] [Related]
4. Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha.
Santoni-Rugiu E; Jensen MR; Thorgeirsson SS
Cancer Res; 1998 Jan; 58(1):123-34. PubMed ID: 9426068
[TBL] [Abstract][Full Text] [Related]
5. Beta-catenin mutations are frequent in hepatocellular carcinomas but absent in adenomas induced by diethylnitrosamine in B6C3F1 mice.
Ogawa K; Yamada Y; Kishibe K; Ishizaki K; Tokusashi Y
Cancer Res; 1999 Apr; 59(8):1830-3. PubMed ID: 10213486
[TBL] [Abstract][Full Text] [Related]
6. Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin.
Harada N; Miyoshi H; Murai N; Oshima H; Tamai Y; Oshima M; Taketo MM
Cancer Res; 2002 Apr; 62(7):1971-7. PubMed ID: 11929813
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of glutamine synthetase is associated with beta-catenin-mutations in mouse liver tumors during promotion of hepatocarcinogenesis by phenobarbital.
Loeppen S; Schneider D; Gaunitz F; Gebhardt R; Kurek R; Buchmann A; Schwarz M
Cancer Res; 2002 Oct; 62(20):5685-8. PubMed ID: 12384525
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma in WHV/N-myc2 transgenic mice: oncogenic mutations of beta-catenin and synergistic effect of p53 null alleles.
Renard CA; Fourel G; Bralet MP; Degott C; De La Coste A; Perret C; Tiollais P; Buendia MA
Oncogene; 2000 May; 19(22):2678-86. PubMed ID: 10851067
[TBL] [Abstract][Full Text] [Related]
9. Beta-catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E-cadherin and accumulation of p53, but not with expression of conventional WNT-1 target genes.
Prange W; Breuhahn K; Fischer F; Zilkens C; Pietsch T; Petmecky K; Eilers R; Dienes HP; Schirmacher P
J Pathol; 2003 Oct; 201(2):250-9. PubMed ID: 14517842
[TBL] [Abstract][Full Text] [Related]
10. Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis.
Conner EA; Lemmer ER; Omori M; Wirth PJ; Factor VM; Thorgeirsson SS
Oncogene; 2000 Oct; 19(44):5054-62. PubMed ID: 11042693
[TBL] [Abstract][Full Text] [Related]
11. Ploidy and karyotypic alterations associated with early events in the development of hepatocarcinogenesis in transgenic mice harboring c-myc and transforming growth factor alpha transgenes.
Sargent LM; Sanderson ND; Thorgeirsson SS
Cancer Res; 1996 May; 56(9):2137-42. PubMed ID: 8616862
[TBL] [Abstract][Full Text] [Related]
12. Recurrent allelic deletions at mouse chromosomes 4 and 14 in Myc-induced liver tumors.
Wu Y; Renard CA; Apiou F; Huerre M; Tiollais P; Dutrillaux B; Buendia MA
Oncogene; 2002 Feb; 21(10):1518-26. PubMed ID: 11896580
[TBL] [Abstract][Full Text] [Related]
13. Constitutive expression of mature transforming growth factor beta1 in the liver accelerates hepatocarcinogenesis in transgenic mice.
Factor VM; Kao CY; Santoni-Rugiu E; Woitach JT; Jensen MR; Thorgeirsson SS
Cancer Res; 1997 Jun; 57(11):2089-95. PubMed ID: 9187100
[TBL] [Abstract][Full Text] [Related]
14. Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin.
Cadoret A; Ovejero C; Saadi-Kheddouci S; Souil E; Fabre M; Romagnolo B; Kahn A; Perret C
Cancer Res; 2001 Apr; 61(8):3245-9. PubMed ID: 11309273
[TBL] [Abstract][Full Text] [Related]
15. Mutation of beta-catenin is an early event in chemically induced mouse hepatocellular carcinogenesis.
Devereux TR; Anna CH; Foley JF; White CM; Sills RC; Barrett JC
Oncogene; 1999 Aug; 18(33):4726-33. PubMed ID: 10467420
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of hepatocarcinogenesis in transgenic mouse models of liver cancer.
Calvisi DF; Thorgeirsson SS
Toxicol Pathol; 2005; 33(1):181-4. PubMed ID: 15805070
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of Icat induces G(2) arrest and cell death in tumor cell mutants for adenomatous polyposis coli, beta-catenin, or Axin.
Sekiya T; Nakamura T; Kazuki Y; Oshimura M; Kohu K; Tago K; Ohwada S; Akiyama T
Cancer Res; 2002 Jun; 62(11):3322-6. PubMed ID: 12036951
[TBL] [Abstract][Full Text] [Related]
18. Activation of the canonical Wnt/beta-catenin pathway confers growth advantages in c-Myc/E2F1 transgenic mouse model of liver cancer.
Calvisi DF; Conner EA; Ladu S; Lemmer ER; Factor VM; Thorgeirsson SS
J Hepatol; 2005 Jun; 42(6):842-9. PubMed ID: 15885355
[TBL] [Abstract][Full Text] [Related]
19. [Role of Wnt/beta-catenin signaling transduction pathway in rat hepatocarcinogenesis].
Wang QM; Li X; Jia LQ; Yang KM; Zhou HY; Yang HJ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Jul; 22(4):454-7. PubMed ID: 16806007
[TBL] [Abstract][Full Text] [Related]
20. Lymphoid enhancer factor 1 makes cells resistant to transforming growth factor beta-induced repression of c-myc.
Sasaki T; Suzuki H; Yagi K; Furuhashi M; Yao R; Susa S; Noda T; Arai Y; Miyazono K; Kato M
Cancer Res; 2003 Feb; 63(4):801-6. PubMed ID: 12591729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
